IMRX
Immuneering Corp - Class A
NASDAQ · Biotechnology
$4.93
+0.41 (+9.07%)
Open$4.62
Previous Close$4.52
Day High$5.02
Day Low$4.60
52W High$3.33
52W Low$1.38
Volume—
Avg Volume131.1K
Market Cap318.33M
P/E Ratio26.44
EPS$0.10
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
-28.2% upside
Current
$4.93
$4.93
Target
$3.54
$3.54
$2.50
$3.54 avg
$3.55
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 183.49M | 183.65M | 175.87M |
| Net Income | 12.93M | 12.84M | 10.17M |
| Profit Margin | 7.1% | 7.0% | 5.8% |
| EBITDA | 22.71M | 20.96M | 19.85M |
| Free Cash Flow | 10.88M | 9.00M | 9.93M |
| Rev Growth | -6.7% | +18.5% | +10.5% |
| Debt/Equity | 0.36 | 0.44 | 0.35 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |